THE USE OF THE MPTP-TREATED MOUSE AS AN ANIMAL-MODEL OF PARKINSONISM
THE USE OF THE MPTP-TREATED MOUSE AS AN ANIMAL-MODEL OF PARKINSONISM
复制标题
DOI：
10.1017/s0317167100037860
复制
发表时间：
1987-08-01
影响因子：
3
通讯作者：
SONSALLA, PK
中科院分区：
文献类型：
--
作者：
HEIKKILA, RE;SONSALLA, PK
经mptp治疗的小鼠已被证明是一个有价值的帕金森病模型。例如，经MPTP处理的C57黑鼠新纹状体多巴胺及其代谢物含量大幅下降，新纹状体突触体积累[3H]多巴胺的能力显著降低，新纹状体酪氨酸羟化酶活性大幅下降，黑质致密带神经细胞明显减少，行为明显缺陷。这些生化、病理和行为缺陷在mptp治疗的灵长类动物和特发性帕金森患者中也同样存在。我们目前对MPTP的许多认识都来自于在老鼠身上进行的实验。
The MPTP-treated mouse has proven to be a valuable model of parkinsonism. For example, C57 black mice treated with MPTP exhibit a large decrement in the neostriatal content of dopamine and its metabolites, a marked reduction in the capacity of neostriatal synaptosomal preparations to accumulate [3H]dopamine, a large decrease in neostriatal tyrosine hydroxylase activity, a marked loss of nerve cells in the zona compacta of the substantia nigra, and pronounced behavioral deficits. These biochemical, pathological and behavioral deficits are similarly observed in MPTP-treated primates and in humans with idiopathic parkinsonism. A great deal of our current knowledge concerning MPTP has come from experimentation carried out in the mouse.